KLK3 and neutropenia: A phase II trial found that a weekly treatment schedule of 10 mg/m2 of docetaxel resulted in a 34.9% prostate-specific antigen (PSA) response rate, with lower toxicity rates of 14.2% neutropenia and 35.7% diarrhea [33].